Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Trading Update

19 Jan 2010 07:00

RNS Number : 7435F
Cello Group plc
19 January 2010
 



19 January 2010

  

Cello Group plc

Pre-Close trading update - year ended 31 December 2009

Cello Group plc (AIM: CLL, 'the Group'),  the leading independent market research and consulting group, today publishes the following pre-close trading update for the year ended 31 December 2009 Since the announcement of the Group's interim results published in early September, there has been a marked pick up in its market research activity from a wide range of domestic and international clients, in addition to continued strength in the core pharmaceutical operation. However, this has been offset by a challenging period for aspects of the Tangible division of the Group, most notably in financial services and certain charity related work where the traditional seasonal pick up in client activity was not as robust as anticipated. The Tangible operations based in Scotland have had a strong year. Total Group revenue is expected to be in the region of £60.0m.

As highlighted in the interim results, the Group's cost reduction programme continued in the second halfThe total cost base in 2009 is expected to be between £4.0m and £4.5m lower than 2008 as a result of reduced headcount and property consolidation, which will give rise to an exceptional cost of around £1.9m.

As a result, the Board anticipates that the Group's headline profit before tax will be approximately £5.0m.The Group's strong cash conversion continued in the second half of 2009, as a result of which the Board expects to report year end net debt of between £11.5m and £12.0m, down from £14.8m on 30 June 2009.Whilst the Board remains realistically cautious about the current outlook and it is too early to give detailed guidance for 2010, the Group is seeing refreshed levels of spend across major research clients, with pharmaceutical and health related research showing particular strengthThe pipeline of research work is significantly stronger than at the same time last year. Therefore, following the substantial reduction in low margin and non-profitable activities, the Group is in a strong position to push for organic growth in 2010. The Group expects to announce its preliminary results for the year ended 31 December 2009 on Wednesday 17 March 2010. 

 

Enquiries:

 

Cello Group 

 020 7812 8460

Mark ScottChief Executive

Mark Bentley, Finance Director

 

Altium 

 020 7484 4040

Ben Thorne

Paul Chamberlain

 

College Hill

 020 7457 2020

Adrian Duffield/Rozi Morris

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXFPFELEEFF
Date   Source Headline
2nd Oct 20198:40 amRNSDisposal
18th Sep 20197:00 amRNSInterim Results
23rd Aug 201910:40 amRNSHolding(s) in Company
16th Aug 20197:00 amRNSAcquisition of ISS
6th Aug 20193:07 pmRNSTotal Voting Rights
6th Aug 20197:00 amRNSNotification of Half Year Results
18th Jul 20197:00 amRNSPre-close Trading Update
20th Jun 20194:29 pmRNSDirector/PDMR Shareholding
10th Jun 20199:41 amRNSTotal Voting Rights
24th May 201912:45 pmRNSBlock listing Interim Review
20th May 20194:29 pmRNSIssue of Equity
15th May 20197:00 amRNSHolding(s) in Company
8th May 20191:30 pmRNSResult of AGM
8th May 20197:00 amRNSAGM Statement
1st May 201912:15 pmRNSTotal Voting Rights
15th Apr 201911:12 amRNSAnnual Report and Notice of AGM
10th Apr 20197:00 amRNSCapital Markets Event
4th Apr 201910:00 amRNSTotal Voting Rights
27th Mar 20191:00 pmRNSHolding(s) in Company
21st Mar 20193:10 pmRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSPreliminary Results
6th Mar 20191:51 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSNotice of Full Year Results
17th Jan 20197:00 amRNSPre-Close Trading Statement
14th Dec 20189:24 amRNSBlock Listing Update
23rd Nov 20183:45 pmRNSHolding(s) in Company
19th Nov 20182:45 pmRNSHolding(s) in Company
12th Nov 201811:30 amRNSDirectorate Change
5th Nov 20182:00 pmRNSDirectorate Change
31st Oct 20183:30 pmRNSDirector/PDMR Shareholding
10th Oct 20187:00 amRNSDirector/PDMR Shareholding
2nd Oct 20187:00 amRNSAppointment of Executive Director
25th Sep 20181:00 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 201811:39 amRNSTransfer of FTSE classification to Healthcare
21st Sep 201810:15 amRNSDirector/PDMR Shareholding
20th Sep 20184:00 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSDirector/PDMR Shareholding
19th Sep 20187:00 amRNSInterim Results
22nd Aug 20181:51 pmRNSHolding(s) in Company
17th Aug 20187:00 amRNSNotification of Half Year Results
16th Aug 20182:00 pmRNSTotal Voting Rights
16th Aug 20181:30 pmRNSBoard Changes
23rd Jul 20187:00 amRNSHolding(s) in Company
19th Jul 20187:00 amRNSPre-close Trading Update
17th Jul 20187:00 amRNSChange of registered office
4th Jul 20181:53 pmRNSHolding(s) in Company
27th Jun 201812:46 pmRNSHolding(s) in Company
22nd Jun 20184:47 pmRNSHolding(s) in Company
20th Jun 20182:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.